Synthetic cytokine circuits that drive T cells into immune-excluded tumors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36520915.
- Also identified by DOI 10.1126/science.aba1624 and PMC identifier 9970000.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with immunosuppressive microenvironments. To overcome suppression, we engineered circuits in which tumor-specific synNotch receptors locally induce production of the cytokine IL-2. These circuits potently enhance CAR T cell infiltration and clearance of immune-excluded tumors, without systemic toxicity. The most effective IL-2 induction circuit acts in an autocrine and T cell receptor (TCR)- or CAR-independent manner, bypassing suppression mechanisms including consumption of IL-2 or inhibition of TCR signaling. These engineered cells establish a foothold in the target tumors, with synthetic Notch-induced IL-2 production enabling initiation of CAR-mediated T cell expansion and cell killing. Thus, it is possible to reconstitute synthetic T cell circuits that activate the outputs ultimately required for an antitumor response, but in a manner that evades key points of tumor suppression.
Medical subject headings
- Immunotherapy, Adoptive
- Interleukin-2
- Neoplasms
- T-Lymphocytes
- Receptors, Chimeric Antigen
- Immunosuppression Therapy